Production small banner


uNiK logo

Glycostem has translated the natural process of differentiation of blood building stem cells to Natural Killer (NK) cells into a clinical scale and clinical grade NK cell production method. Off-the-shelf umbilical cord blood units are processed within our production platform uNiK®, a completely closed system in a class C clean room environment with own cell expansion technology.

The oNKord® biobank consists of universal, "off-the-shelf" units, that can be shipped to clinical sites. These units contain highly functional Natural Killer cells with high cytotoxicity versus malignant cells. oNKord® effector cells are activated and "ready to attack cancer cells", not requiring additional in vivo activation. oNKord® batches can produce cell products for up to 8 patients allowing for production of cell products for 100 patients per year in a small facility and being scalable to 800 and 1000 patients per year, providing a cell product that can be made available to many patients.



Umbilical cord blood is a rich source of stem cells. Collection of cord blood is not associated with risks of donation and thus required ethical limitations of donation for generation of a cell therapy product. Cord blood is available as long as mankind continues to reproduce.

Transfer steps between different disposables for processing devices are performed by sterile welding. Starting material, intermediate stages of the cell product and the final oNKord® cell product are never exposed to a risk of contamination.

oNKord® production process

1-2: CD34+ hematopoietic stem cells are collected from cord blood units.

3: NK cell progenitor cells are expanded from stem cells within 2 weeks of static culture in a cell culture bag in an incubator; this exposes the cells to two different cytokine cocktails to promote expansion of NK cell progenitor cells over progenitor cells of other cell lineages.

4: Progenitor cells are then transferred to a rocking bioreactor to differentiate into fully functional NK cells and increase their number.

5: NK cells from a culture volume of up to 8 liters are then harvested using a continuous centrifugation process. Cell culture medium is washed out and NK cells are resuspended in an infusion grade solution.

6: Re-suspended NK cells are supplemented with a cryoprotectant and the solution is then filled with fixed cell count, cell concentration and filling volume into cryoconservation bags

7: oNKord® units are cryopreserved using a controlled rate freezer

8: oNKord® units are then banked for use.

oNKord manufacturing process